$990.9 million in 2026 is projected to grow to $3.334 billion by 2036, with demand driven by hospitals seeking bedside brain imaging that avoids risky patient transfers during acute neurological care.
12.9% annual growth rests on whether portable systems deliver clinically useful scans near the patient without raising repeat imaging, staffing strain, or unclear escalation to conventional MRI.
37.3% of the 2026 market is expected to come from low-field systems, while stroke diagnosis and hospitals each account for 34.1% and 37.3%, reflecting the strongest use case in acute inpatient pathways.
200-plus installed Hyperfine systems and roughly 250,000 images provide an early commercial benchmark, but adoption still depends on regulatory clearance, local service support, radiology coverage, and procurement rules.
15.8% growth in Japan and 15.4% in South Korea lead the country outlook, while the U.S. and U.K. trail at 12.8% and 11.6% as national approval and purchasing routes diverge.